Aytu BioScience ( (AYTU) ) has released its Q4 earnings. Here is a breakdown of the information Aytu BioScience presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Aytu BioPharma, Inc. is a pharmaceutical company dedicated to developing innovative treatments for complex central nervous system diseases, with a focus on improving patient quality of life. The company offers prescription products for conditions such as major depressive disorder and ADHD.
In its fiscal 2025 earnings report, Aytu BioPharma announced a net revenue of $66.4 million, marking a 2% increase from the previous year. Despite a net loss of $13.6 million, the company is optimistic about its future, particularly with the upcoming launch of EXXUA™, a novel treatment for major depressive disorder.
Key financial highlights include a stable ADHD portfolio with $57.6 million in revenue and a growing pediatric portfolio, which saw a 20% increase to $8.8 million. The company’s adjusted EBITDA was $9.2 million, reflecting a slight decrease from the previous year. Aytu also reported a cash balance of $31.0 million as of June 30, 2025.
Strategically, Aytu is set to launch EXXUA in the fourth quarter of 2025, entering the $22 billion U.S. market for major depressive disorder treatments. The company is finalizing manufacturing and preparing promotional materials, positioning EXXUA as a significant growth catalyst.
Looking forward, Aytu BioPharma aims to establish itself as a leading CNS-focused company, leveraging the commercial potential of EXXUA and its existing product portfolio to drive growth and improve patient outcomes.